Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard treatment modality for stage IV NSCLC patients harboring EGFR-sensitive mutations [1, 2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.